Skip to main content
logo
Lytix Biopharma ASA (OSL:LYTIX)
Norway flag Norway · Delayed Price · Currency is NOK
7.70
+0.20 (2.67%)
Aug 24, 2026, 9:07 AM CET

Lytix Biopharma ASA Financials Overview

Millions NOK. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
--11.133.9911.0319.31
Revenue Growth
--178.98%-63.82%-42.86%373.91%
Gross Profit
--11.133.9911.0319.31
Operating Income
-77.39-64.03-95.9-96.79-65.67-47.99
Net Income
-73-59.98-94.27-87.9-56.07-48.08
Earnings Per Share
--0.88-1.74-2.19-1.41-1.45
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
120.1772.36130.7950.55145.16197.28
Total Debt
2.022.22.640.491.342.17
Net Cash (Debt)
118.1670.16128.1550.06143.81195.11
Net Cash Growth
2.73%-45.25%156.01%-65.19%-26.29%585.80%
Net Cash Per Share
-1.032.371.253.635.88

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-75.74-59.85-70.37-95.97-52.63-44.61
Capital Expenditures
----0.05-0.15-
Free Cash Flow
-75.74-59.85-70.37-96.02-52.78-44.61
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
--100.00%100.00%100.00%100.00%
Operating Margin
---861.29%-2425.08%-595.28%-248.54%
Pretax Margin
---846.64%-2202.38%-508.29%-249.02%
Profit Margin
---846.64%-2202.38%-508.29%-249.02%
FCF Margin
---632.05%-2405.86%-478.47%-231.04%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
--36.0548.7928.1927.59